Drug
Upadacitinib 15 MG
Upadacitinib 15 MG is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
17%
Ph phase_4
1
17%
Ph phase_1
1
17%
Ph phase_3
1
17%
Ph phase_2
1
17%
Ph early_phase_1
1
17%
Phase Distribution
2
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(4)
Completed(2)
Detailed Status
Completed2
Not yet recruiting2
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 41 (16.7%)
N/A1 (16.7%)
Trials by Status
completed233%
not_yet_recruiting233%
recruiting233%
Recent Activity
2 active trials
Showing 5 of 6
completedphase_2
Upadacitinib for Refractory Behcet's Syndrome
NCT07080346
completedphase_3
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF
NCT06758947
recruitingnot_applicable
Efficacy of Upadacitinib After NECS in Vitiligo
NCT06454461
not_yet_recruitingphase_4
JAK Inhibitor Dose TAPering Strategy Study
NCT06687551
not_yet_recruitingearly_phase_1
Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis
NCT06684522
Clinical Trials (6)
Showing 6 of 6 trials
NCT07080346Phase 2
Upadacitinib for Refractory Behcet's Syndrome
NCT06758947Phase 3
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF
NCT06454461Not Applicable
Efficacy of Upadacitinib After NECS in Vitiligo
NCT06687551Phase 4
JAK Inhibitor Dose TAPering Strategy Study
NCT06684522Early Phase 1
Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis
NCT06379958Phase 1
Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6